Totally Agree...with positive R-it results and a 30% RRR it is only PFE, MRK or NVS that could probably afford them if they decide that is the best solution.
My take is that "if" AMRN is acquired by BP it will be the winner of a bidding war for the company. The only BP that will win is the one who has the buying power and the foresight to figure out the future revenue potential for some of the potential uses of Vascepa both within CVD and outside of CVD. Best guess as to a buyout price range I would place at $20-$32 a share.
Market Data 
Markets 
AI
